Whitehawk Therapeutics Inc
Whitehawk Therapeutics Inc (WHWK) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
whwk · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Whitehawk Therapeutics IncYou WHWK | $199M | N/A | — | — |
 Atossa Therapeutics, Inc. ATOS | $39M | N/A | — | -$4.04 |
 Clene Inc. CLNN | $58M | N/A | — | -$2.65 |
 Context Therapeutics Inc. CNTX | $154M | N/A | — | -$0.38 |
 Immix Biopharma, Inc. IMMX | $435M | N/A | — | -$0.89 |
 MacroGenics, Inc. MGNX | $257M | N/A | — | -$1.18 |
 Oncolytics Biotech Inc. ONCY | $86M | N/A | — | -$0.41 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Whitehawk Therapeutics Inc (WHWK) measures how much investors pay for each dollar of the company's trailing earnings. WHWK's current PE ratio of N/A is calculated by dividing its stock price of $4.02 by its TTM earnings per share of —.
Frequently asked questions
WHWK pe ratio · 6 questionsWHWK's current PE ratio is N/A as of 2026-06-09, based on a stock price of $4.02 and TTM EPS of —. Data sourced from Financial Modeling Prep via WHWK's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Whitehawk Therapeutics Inc SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09